The authors reply
As correctly pointed out by the authors, arterial blood pressure (ABP) zeroing has implications with regard to the guideline thresholds. The vast majority of data reported in our study (2) is from the period where ABP was zeroed at right atrium level (1996–2015); however, from March of 2015, the zero level was adjusted to Monro level (3). Thus, the reported absolute CPP values for periods before 2015 will be somewhat higher than the CPP values thereafter; however, it should be noted that the difference between actual CPP and a position on the CPP-pressure reactivity index (PRx) curve (CPPoptimal [CPPopt], CPP lower limit of reactivity [LLR], or CPP upper limit of reactivity [ULR]) will not depend on ABP transducer zero level. Complicating matters, the final cerebral arterial blood pressure will depend on additional, generally unmeasured factors such as wave reflection, vessel geometry, and luminal obstructions. For example, if a patient has a significant carotid stenosis, the pressure measured at the level of the radial artery would be significantly higher (~50 mm Hg) than at middle cerebral artery level (4).
The current method of estimating CPPopt and limits of (vascular) reactivity uses a series of heuristic constraints in attempt to produce reliable values that fit the autoregulation concept (5). This selection process has the obvious clinical disadvantage of decreasing the CPPopt yield. To increase the yield, we used a multiple window averaging algorithm (6), which uses data from multiple time windows of different length to give an averaged CPPopt, LLR, or ULR. Using this algorithm, the yield of LLR, ULR, and CPPopt increased to 93% of monitoring time. The proportion of time that LLR or ULR were extrapolations, rather than values experienced by the patient within the time window, was not calculated.
Completely disturbed autoregulation represents a challenge for an automated CPP target recommendation algorithm such as ours. As stated in the methods, if autoregulation was impaired across all levels of CPP (i.e., the whole autoregulation curve is above PRx of 0.3—occurring on average 6.07% [SD, 13.73%] of the valid monitoring time), then the value for CPPopt was taken to be both the LLR and ULR. This insured that any CPP value during globally impaired autoregulation was classified as “outside” the CPP limits of reactivity. However, one could also argue that no LLR, ULR, or CPPopt recommendation should be given when no CPP is associated with adequate cerebral autoregulation.
Although a CPP that is too low is clearly detrimental in that it leads to cerebral ischemia, the cerebral effects of high CPP are less clearly defined. In addition, theoretical risks of maintaining high CPP include damage to other organs. The unknown feasibility, effectiveness, and potential risks of a CPPopt guided therapy are the impetus for the upcoming CPPopt-Guided Therapy trial of Target Effectiveness in traumatic brain injury patients (COGITATE, www.cppopt.org, clinical trial number: NCT02982122).